Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oocyte-F
- Development stage
- Unknown
- Lead developer
- FEMA Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oocyte-F is an oral nutraceutical supplement developed and marketed by Fema Health Care (FEMA), an Indian pharmaceutical company based in Chennai. The product is formulated as a capsule and is specifically designed for women's health, with a focus on supporting reproductive function and oocyte quality. As a commercial nutraceutical, it is typically used to manage conditions such as Polycystic Ovary Syndrome (PCOS) and to improve fertility outcomes. While the exact composition is not specified in the company's high-level product list, supplements of this type in the Indian market generally contain a blend of insulin-sensitizing agents like inositols and various antioxidants and vitamins.
- Brand names
- Oocyte-F
Beyond the preview
Go deeper on Oocyte-F.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oocyte-F.